Xian-Janssen, a division of Johnson & Johnson, has launched a new drug in China. Dacogen (decitabine), a novel treatment for myelodysplastic syndrome (MDS), received SFDA approval through the Green Channel, an expedited approval process that the SFDA introduced in January 2009. In Dacogen’s case, the SFDA allowed Xian-Janssen to begin marketing the drug in China based on trials done ex-China. More details...

Stock Symbol: (NYSE: JNJ)